Correspondence 0001193125-25-061425 from Amylyx Pharmaceuticals, Inc. (AMLX)
Amylyx Pharmaceuticals, Inc.
Date: March 24, 2025 · CIK: 0001658551 · Accession: 0001193125-25-061425
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-285525
Letter
Re: Amylyx Pharmaceuticals, Inc. Acceleration Request for Registration Statement on Form S-3 File No. 333-285525 Ladies and Gentlemen: Pursuant to Rule 461 under the Securities Act of 1933, as amended (the “ Act ”), Amylyx Pharmaceuticals, Inc. (the “ Company ”) hereby requests that the effective date of the above-referenced registration statement (the “ Registration Statement ”) be accelerated to March 26, 2025, at 5:00 p.m., Eastern Time, or as soon thereafter as practicable, unless we or our outside counsel, Goodwin Procter LLP, request by telephone that such Registration Statement be declared effective at some other time. In making this acceleration request, the Company acknowledges that it is aware of its responsibilities under the Act. Once the Registration Statement is effective, please orally confirm the event with our counsel, Goodwin Procter LLP by calling Marishka DeToy at (617) 570-1926. If you have any questions regarding this request, please contact Marishka DeToy of Goodwin Procter LLP at (617) 570-1926.
VIA EDGAR March 24, 2025 United States Securities and Exchange Commission Office of Life Sciences Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549
Sincerely,
AMYLYX PHARMACEUTICALS, INC.
Show Raw Text
CORRESP 1 filename1.htm CORRESP VIA EDGAR March 24, 2025 United States Securities and Exchange Commission Office of Life Sciences Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: Amylyx Pharmaceuticals, Inc. Acceleration Request for Registration Statement on Form S-3 File No. 333-285525 Ladies and Gentlemen: Pursuant to Rule 461 under the Securities Act of 1933, as amended (the “ Act ”), Amylyx Pharmaceuticals, Inc. (the “ Company ”) hereby requests that the effective date of the above-referenced registration statement (the “ Registration Statement ”) be accelerated to March 26, 2025, at 5:00 p.m., Eastern Time, or as soon thereafter as practicable, unless we or our outside counsel, Goodwin Procter LLP, request by telephone that such Registration Statement be declared effective at some other time. In making this acceleration request, the Company acknowledges that it is aware of its responsibilities under the Act. Once the Registration Statement is effective, please orally confirm the event with our counsel, Goodwin Procter LLP by calling Marishka DeToy at (617) 570-1926. If you have any questions regarding this request, please contact Marishka DeToy of Goodwin Procter LLP at (617) 570-1926. Sincerely, AMYLYX PHARMACEUTICALS, INC. /s/ Joshua B. Cohen Joshua B. Cohen Co-Chief Executive Officer /s/ Justin B. Klee Justin B. Klee Co-Chief Executive Officer cc: James M. Frates, Amylyx Pharmaceuticals, Inc. Benjamin K. Marsh, Goodwin Procter LLP Marishka DeToy, Goodwin Procter LLP